Abstract OBJECTIVE: To investigate whether topotecan, a novel anti-tumor angent, down-regulates gene expression of melanoma antigen-encoding (MAGE) in HPB-AM cells. METHODS: MAGE mRNA expression of HPB-AM cells was detected by RT-PCR 4, 8, 12 and 16 hrs after different concentrations (0.05, 0.10, 0.15 and 0.20 μmol/L) of topotecan treatment. RESULTS: MAGE mRNA expression of HPB-AM cells decreased with increasing concentrations of topotecan 12 hrs after treatment. The MAGE mRNA expression of HPB-AM cells treated by 0.10, 0.15 and 0.20 μmol/L of topotecan was significantly lower than that in the blank control group (P<0.05). MAGE mRNA expression of HPB-AM cells was significantly reduced in a time-dependent manner after 0.10 μmol/L of topotecan treatment. The MAGE mRNA expression of HPB-AM cells treated by 0.10 μmol/L of topotecan was significantly lower than that in the blank control group 12 and 16 hrs after treatment (P<0.05). CONCLUSIONS: Topotecan is capable of inhibiting the expression of MAGE mRNA of HPB-AM cells in a time- and dose-dependent manner.［Chin J Contemp Pediatr, 2009, 11 (8):679-682］
［1］van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma［J］. Science, 1991, 254(5038):1643-1647.
［2］Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLAA1［J］. Int J Cancer, 1999, 80(2):219-230.
3.0.CO;2-S target="_blank">
［3］De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family［J］. Immunogenetics, 1994, 40(5):360-369.
［4］Muscatelli F, Walker AP, De Plaen E, Stafford AN, Monaco AP. Isolation and characterization of a MAGE gene family in the Xp21.3 region［J］. Proc Natl Acad Sci USA, 1995, 92(11):4987-4991.
［5］Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, et al. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin′s lymphoma: a National Cancer Institute of Canada Clinical Trials Group study［J］. Leuk Lymphoma, 2002, 43(8):1581-1587.
［6］Russo V, Dalerba P, Ricci A, Bonazzi C, Leone BE, Mangioni C, et al. MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas［J］. Int J Cancer, 1996, 67(3):457-460.
3.0.CO;2-3 target="_blank">
［7］Hara I, Hara S, Miyake H, Yamanaka K, Nagai H, Gohji K, et al. Expression of MAGE genes in testicular germ cell tumors［J］. Urology, 1999, 53(4):843-847.
［8］Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts［J］. Br J Cancer, 1995, 71(3):525-528.
［9］De Smet C, Courtois SJ, Faraoni I, Lurquin C, Szikora JP, De Backer O, et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene［J］. Immunogenetics, 1995, 42(4):282-290.
［10］Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW,et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells［J］. Br J Cancer, 2002, 86(1):110-116.
